You are here: Home: Audio Program Guide: BCU 1 | 2007 Audio: BCU 1 | 2007
 
  Go to interview with Larry Norton, MD
Go to interview with Hyman B Muss, MD
Go to interview with Joseph A Sparano, MD
Go to Roundtable Discussion



 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Norton, MD Interview with Larry Norton, MD
Deputy Physician-in-Chief
Memorial Hospital for Breast Cancer Programs
Norna S Sarofim Chair in Clinical Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Cancer as a “self-seeding” disease
Track 3 Identification of site-specific metastasis genes and functions
Track 4 Self-seeding as a potential biological explanation for cancer characteristics
Track 5 Therapeutic implications of self-seeding
Track 6 Self-seeding predicts Gompertzian tumor growth

Track 7 Self-seeding and identification of novel therapeutic targets
Track 8 Anti-angiogenic therapy as a critical component of cancer treatment
Track 9 Potential rationale for the use of bevacizumab in the adjuvant setting
Track 10 Advantages of neoadjuvant clinical trials in the rational development of agents and combinations
Track 11 Evaluation of gene copy number and genetic mutations
Track 12 Characteristics of molecules associated with metastasis
Track 13 Implications of the self-seeding hypothesis for cancer prevention
Track 14 Relationship between the self-seeding hypothesis and the effectiveness of dose-dense scheduling
Track 15 Studies evaluating alternative scheduling and dosing of capecitabine
Track 16 Improved toxicity profile of dose-dense versus conventionally scheduled chemotherapy
Track 17 Adjuvant dose-dense ACpaclitaxel/trastuzumab
     
Muss, MD Hyman B Muss, MD
Professor of Medicine
University of Vermont
College of Medicine
and Vermont Cancer Center
Burlington, Vermont
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Toxicity in older and younger patients treated with adjuvant chemotherapy: The CALGB experience
Track 3 Mortality comparison of the CALGB elderly population to a matched national population
Track 4 CALGB adjuvant trial 49907: Capecitabine versus AC or CMF in elderly patients
Track 5 Quality of life and compliance subprotocols in CALGB-49907
Track 6 Correlative science and toxicity studies on CALGB-49907

Track 7 Effect of adjuvant chemotherapy on cardiac function
Track 8 Counseling patients about the cardiac risk associated with adjuvant chemotherapy
Track 9 Adjuvant docetaxel/cyclophosphamide (TC) versus AC
Track 10 Evaluating schedule, dose and chemotherapy combinations of capecitabine in the adjuvant setting
Track 11 Use of capecitabine with bevacizumab as firstline therapy
Track 12 Upcoming and ongoing adjuvant clinical trials
Track 13 Incorporation of nanoparticle albumin-bound (nab) paclitaxel into the adjuvant setting
Track 14 Offering clinical trial participation to elderly patients
Track 15 Selection of elderly patients for treatment with adjuvant chemotherapy
Track 16 Selection of adjuvant chemotherapy for patients with hormone receptor-negative, node-positive disease
Track 17 Use of adjuvant dose-dense AC without a taxane
     
Sparano, MD Joseph A Sparano, MD
Professor of Medicine and Women’s Health
Albert Einstein College of Medicine
Associate Chairman
Department of Oncology
Montefiore Medical Center
Director, Breast Evaluation Center
Montefiore-Einstein Cancer Center
Bronx, New York
 
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Background and design of ECOG adjuvant trial E1199 evaluating AC followed by paclitaxel or docetaxel every three weeks or weekly
Track 3 ECOG-E1199: Efficacy results
Track 4 ECOG-E1199: Side effects and toxicity
Track 5 ECOG-E1199: Conclusions
Track 6 Patient and treatment characteristics in E1199

Track 7 Impact of hormone receptor status on response to adjuvant chemotherapy
Track 8 Selection of adjuvant chemotherapy for patients with node-positive disease
Track 9 Docetaxel/cyclophosphamide as an alternative to adjuvant AC
Track 10 Use of nab versus standard paclitaxel in clinical practice
Track 11 Selection of adjuvant chemotherapy for patients with HER2-positive disease
Track 12 Program for the Assessment of Clinical Cancer Tests (PACCT)
Track 13 Use of the Oncotype DX™ multigene breast cancer assay in TAILORx
Track 14 TAILORx: Hormonal therapy with or without chemotherapy for node-negative breast cancer with various levels of risk for recurrence
Track 15 Rationale for the recurrence score criteria for patients randomly assigned to chemotherapy or not in TAILORx
Track 16 Microarray In Node negative Disease may Avoid ChemoTherapy (MINDACT)
     
  Roundtable Discussion
  
  Click here to download the entire discussion  
Track 1 Introduction
Track 2 NSABP-B-40: Randomized trial of six neoadjuvant regimens for patients with operable HER2-negative disease
Track 3 Pathologic complete response as a clinical trial endpoint
Track 4 Correlative science programs in neoadjuvant studies to develop molecular profiles for response to specific agents
Track 5 Proposed NSABP preoperative HER2 trial: ACpaclitaxel with trastuzumab, lapatinib or the combination
Track 6 Evaluating molecularly defined subsets and targeted therapies in clinical trials

Track 7 Evaluating molecularly defined subsets and targeted therapies in clinical trials
Track 8 Toxicity and costs of adjuvant TC versus dose-dense AC chemotherapy
Track 9 Congestive heart failure in older women treated with anthracyclines
Track 10 Considerations in the incorporation of nab paclitaxel into clinical practice
Track 11 Neuropathy associated with standard versus nab paclitaxel
Track 12 Impact of hormone receptor status on responsiveness to chemotherapy
Track 13 Benefits of adjuvant chemotherapy in hormone receptor-positive versus hormone receptor-negative disease
Track 14 Congestive heart failure in older women treated with anthracycline chemotherapy: Analysis of the SEER-Medicare database
Track 15 Case discussion: A 44-year-old woman with a 1.1-cm, ER-positive, PR-negative, HER2-negative, node-negative breast tumor
Track 16 Use of the Oncotype DX assay for patients with lower-risk disease
Track 17 Use of other tumor markers versus the Oncotype DX assay in treatment decision-making
Track 18 Discordance between Oncotype DX and other treatment decision-making algorithms
Track 19 Clinical utility of the Oncotype DX recurrence score in treatment decision-making
Track 20

Case discussion: A 42-year-old woman with a 1-mm, ER-positive, PR-negative, HER2-positive breast tumor with apparent benign mechanical tumor transport to a node
Track 21 Differentiation and treatment of micrometastatic versus benign mechanically transported tumor to a lymph node
Track 22 Case discussion: A 77-year-old woman with a 3-cm, ER-negative, PR-negative, HER2-positive, node-positive tumor
Track 23 Trastuzumab as monotherapy or combined with single-agent chemotherapy
Track 24 Age and trastuzumab-associated risk of cardiac toxicity
Track 25 BIG 2-06 adjuvant HER2 trial of trastuzumab, lapatinib, the sequence or the combination
Track 26 Therapeutic relevance of circulating tumor cells